An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease

NCT07724132 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1200

Enrollment

OTHER

Sponsor class

Conditions

Alzheimer's Disease (AD)
Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer Disease Dementia

Interventions

DRUG: Placebo
DRUG: Atomoxetine
DRUG: Metformin 1000 mg Oral Tablet

Sponsor

University College, London

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]